Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Pfizer shares fall despite upbeat 2018 guidance and market beating fourth quarter numbers

Pfizer expects a "meaningfully lower" effective tax rate this year and a repatriation tax liability of about US$15bn over eight years
Advil
Pfizer Innovative Health was driven by continued strength from several anchor brands

Pfizer Inc (NYSE:PFE) saw its shares turn lower despite the drugmaker providing an upbeat 2018 guidance and releasing forecast-beating fourth quarter numbers.

In the quarter, earnings came in at US$12.27bn, or US$2.02 per share, a sharp rise from US$775mln or 13 US cents per share in the year-earlier period.

READ: Strong pneumonia vaccine sales help Pfizer to top Street estimates

Adjusted earnings-per-share were 62 US cents, beating the market consensus of 56 US cents.

Revenue also rose, but less sharply to rose to US$13.70bn from US$13.63bn, again coming in above market expectations for US$$13.67bn.

Pfizer Innovative Health was driven by continued strength from several anchor brands, including Ibrance, Eliquis and Xeljanz - all of which currently have market-leading positions with many years of patent protection remaining, Chief Executive Ian Read said in a statement.

Its Essential Health business saw strong revenue growth in its emerging markets and biosimilars but was hit by the sale of Hospira Infusion Systems, expected losses of exclusivity for products and Hospira U.S. product shortages.

Pfizer also gave a 2018 revenue guidance of US$53.5bn to US$55.5bn, compared with the market expectations for US$53.82bn.

It also guided 2018 adjusted EPS at between US$2.90 to US$3.00, against market expectations for US$2.78.

READ: FDA sends damning warning letter to Pfizer after misfiring EpiPens linked to deaths

Its 2018 financial guidance for the effective tax rate on adjusted income – seen at about 17% - takes into account the new corporate tax reform.

Pfizer expects a "meaningfully lower" effective tax rate this year and repatriation tax liability of about US$15bn over eight years.

Its 2018 adjusted EPS is also expected to include US5bn in share buybacks, and highlighted plans to invest about US$5bn in capital projects in the U.S.

In early morning trade, Pfizer shares shed 2.8% at US$37.92.

Later in the day, shares shed 3.17% to US$37.78 each.

View full PFE profile View Profile

Pfizer Timeline

Article
November 23 2015

Related Articles

syringe
June 20 2018
“FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain"
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third
Picture of growing facility
May 07 2018
Establishing a vertically integrated business model provides THC with the ability to optimise efficiencies in the manufacturing process.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use